STRATA Skin Sciences Inc
$ 0.25
0.40%
24 Feb - close price
- Market Cap 1,415,400 USD
- Current Price $ 0.25
- High / Low $ 0.29 / 0.20
- Stock P/E N/A
- Book Value 0.25
- EPS -2.63
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -2.04 %
- 52 Week High 3.86
- 52 Week Low 0.12
About
STRATA Skin Sciences, Inc., a medical technology company, develops, markets and markets products for the treatment of dermatological conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company is headquartered in Horsham, Pennsylvania.
Analyst Target Price
$10.80
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-04-28 | 2025-03-25 | 2024-11-12 | 2024-08-14 | 2024-05-15 | 2024-03-27 | 2023-11-14 | 2023-08-09 | 2023-05-15 | 2023-03-31 |
| Reported EPS | -0.36 | -0.6 | -0.58 | 0.2872 | -0.5207 | -0.03 | -0.1 | -0.11 | -0.03 | -0.06 | -0.08 | 0.045 |
| Estimated EPS | 0.03 | 0.01 | -0.56 | -0.4 | -0.44 | -0.7 | -0.07 | -0.02 | -0.04 | -0.05 | -0.07 | -0.05 |
| Surprise | -0.39 | -0.61 | -0.02 | 0.6872 | -0.0807 | 0.67 | -0.03 | -0.09 | 0.01 | -0.01 | -0.01 | 0.095 |
| Surprise Percentage | -1300% | -6100% | -3.5714% | 171.8% | -18.3409% | 95.7143% | -42.8571% | -450% | 25% | -20% | -14.2857% | 190% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SSKN
2026-02-23 19:32:38
STRATA Skin Sciences Inc. (NASDAQ: SSKN) announced that a recent systematic review and meta-analysis published in the Journal of Drugs in Dermatology confirmed the significant efficacy of 308 nm excimer laser therapy for plaque psoriasis. The study, conducted by Georgetown University School of Medicine and MedStar Washington Hospital Center, revealed substantial improvements in PASI scores among patients treated with the excimer laser, typically within 10 to 14 sessions. STRATA's CEO, Dr. Dolev Rafaeli, noted that this analysis reinforces the clinical observations regarding the effectiveness of properly calibrated, MED-guided excimer laser treatment.
2026-02-22 01:04:26
STRATA Skin Sciences (SSKN) saw its stock price drop over 21% despite the announcement that Johns Hopkins Dermatology added the XTRAC 308 nm excimer laser to its clinical offerings. This collaboration aims to enhance precision treatment for chronic skin conditions like psoriasis and vitiligo. The adoption by Johns Hopkins, a leading academic medical center, underscores the growing importance of advanced dermatologic innovation and targeted phototherapy.
2026-02-19 21:30:55
STRATA Skin Sciences (NASDAQ: SSKN) has filed to delist from Nasdaq and "go dark," anticipating cost savings and increased focus on its operating plan. Despite the delisting, the company maintains it has a strong balance sheet with $8 million in cash and that the move is not due to financial instability. CEO Dr. Dolev Rafaeli stated that eliminating compliance burdens will allow the company to better invest in its business and focus on growth opportunities.
2026-02-19 11:59:58
Johns Hopkins Dermatology has integrated the XTRAC® 308 nm excimer laser into its clinical offerings, enhancing its ability to treat chronic inflammatory and autoimmune skin diseases such as psoriasis, vitiligo, and atopic dermatitis. This move strengthens Johns Hopkins' academic leadership in dermatologic care and research. STRATA Skin Sciences, Inc., the developer of XTRAC, emphasizes the importance of precision treatment strategies and collaborations with leading institutions to advance evidence-based dermatologic innovation and expand access to targeted phototherapy.
2026-02-18 19:45:16
Johns Hopkins Dermatology has integrated the XTRAC® 308 nm excimer laser into its clinical offerings, enhancing its capability to treat chronic inflammatory and autoimmune skin conditions like psoriasis, vitiligo, and atopic dermatitis. This move by Johns Hopkins, a leading academic medical center, underscores its commitment to advanced, targeted patient care and clinical research. STRATA Skin Sciences, the developer of XTRAC, emphasizes its continued partnership with top institutions to advance evidence-based dermatologic innovation and expand access to precision treatment strategies.
2026-02-18 13:28:16
Johns Hopkins Dermatology has integrated STRATA Skin Sciences' XTRAC 308 nm excimer laser into its clinical offerings to expand targeted treatment options for inflammatory and autoimmune skin conditions like psoriasis and vitiligo. This collaboration reinforces STRATA Skin Sciences' partnerships with academic centers for advanced dermatologic care and research. Despite the positive clinical news, STRATA Skin Sciences (SSKN) stock experienced a significant decline, indicating a negative market reaction possibly due to broader financial and regulatory concerns.
